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Abstract
Background: Kv10.1, a voltage-gated potassium channel only detected in the healthy brain, was found to be
aberrantly expressed in extracerebral cancers. Investigations of Kv10.1 in brain metastasis and glioblastoma
multiforme (GBM) are lacking.
Methods: We analyzed the expression of Kv10.1 by immunohistochemistry in these brain tumors (75 metastasis
from different primary tumors, 71 GBM patients) and the influence of a therapy with tricyclic antidepressants (which
are Kv10.1 blockers) on survival. We also investigated Kv10.1 expression in the corresponding primary carcinomas of
metastases patients.
Results: We observed positive Kv10.1 expression in 85.3 % of the brain metastases and in 77.5 % of GBMs. Patients
with brain metastases, showing low Kv10.1 expression, had a significantly longer overall survival compared to those
patients with high Kv10.1 expression. Metastases patients displaying low Kv10.1 expression and also receiving
tricyclic antidepressants showed a significantly longer median overall survival as compared to untreated patients.
Conclusions: Our data show that Kv10.1 is not only highly expressed in malignant tumors outside CNS, but also in
the most frequent cerebral cancer entities, metastasis and GBM, which remain incurable in spite of aggressive
multimodal therapies. Our results extend the correlation between dismal prognosis and Kv10.1 expression to
patients with brain metastases or GBMs and, moreover, they strongly suggest a role of tricyclic antidepressants for
personalized therapy of brain malignancies.
Keywords: Kv10.1, Potassium channel, Ion-channel, Brain metastases, Glioblastoma multiforme, Protein expression,
Survival time, Tricyclic antidepressants, Tailored therapy
Background
Kv10.1 (Ether-à-go-go-1, KCNH1, Eag1) is a voltage-gated
potassium channel, the expression of which is limited to se-
lected brain areas such as hypothalamus, hippocampus,
cerebral cortex, cerebellum and olfactory nerve [1]. It plays
key roles in different physiological functions such as activa-
tion of excitable cells, hormone secretion regulation, cell to
cell signal transduction, homeostasis of both blood pressure
and osmoregulation of intracellular milieu [2]. Strikingly,
Kv10.1 was also found to be a key player in regulation of
cell division and proliferation [3] and overexpression has
been detected at a very high rate (>75 %) in breast, renal
and cervical carcinoma cell lines [4] as well as in different
human malignancies, for instance colorectal [5] and cer-
vical cancer [6], soft tissue sarcomas [7], acute myeloid
leukemia [8], esophageal and gastric cancer [9, 10], head
and neck carcinomas [11], ovarian [12], breast, lung and
prostate cancer [13]. Aberrant expression of Kv10.1 has also
been observed in regional lymph node metastases of gastric
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cancer and esophageal squamous cell carcinoma [10, 14].
Underscoring the oncological relevance of Kv10.1, previous
analyses have recognized a correlation between the expres-
sion of Kv10.1 and patient prognosis. High Kv10.1 expres-
sion was associated with shorter overall survival of patients
with esophageal and ovarian carcinomas [10, 12] as well as
acute myeloid leukemia [8].
Although many efforts were made to unravel the role
of Kv10.1 in cancer over years, the precise mechanisms
remain only partially understood [15]. Previous investi-
gations showed the relevance of Kv10.1 in cell cycle
regulation [3] and proliferation control of tumor cells
[4]. Laboratory data further indicated that aberrant ex-
pression of Kv10.1 is not an early event in pathogenesis,
since aberrant Kv10.1 expression can be observed in ex-
perimental tumor models in which cancer had been trig-
gered by further well established pathways [16]. A
possible mechanism may be that Kv10.1 favors tumor
progression through stimulating neo-angiogenesis via
up-regulation of HIF-1 and VEGF in a tumor environ-
ment characterized by extreme hypoxia [17]. Loss of
contact inhibition, accelerated proliferation [4] and in-
creased migration [18] can also contribute to tumor pro-
gression, and therefore also non-solid tumors can
benefit from Kv10.1 expression [8].
Since activity experiments of the Kv10.1 channel indi-
cate cell membrane localization [6] the possibility to se-
lectively block the channel was investigated. Blockade of
Kv10.1 expression by specific monoclonal antibody [19]
siRNA [20] or shRNA [21] led to reduced tumor cell pro-
liferation and reduced tumor progression both in vitro
[22] and in vivo [17, 19]. Furthermore, drug induced
blockade of Kv10.1 expression, with the tricyclic anti-
depressant (TA) imipramine [22] and with astemizole in
breast cancer cells [23], in both cases with IC50 in the low
micromolar range, resulted in anti-tumorigenic effects.
Furthermore, astemizole was found to increase calcitriol-
induced antiproliferative activity in breast cancer by tar-
geting Kv10.1, inhibiting CYP24A1 and up-regulating
VDR [24]. Although ion channels are not the primary tar-
gets of imipramine or astemizole, both drugs block differ-
ent channels with relatively high affinity by binding to
intracellular regions; astemizole has been described to
block several K+ channels related to Kv10.1, and imipra-
mine blocks Na+, K+ and Ca2+ channels in different prepa-
rations [25].
Concerning GBM, only spare data with inconclusive
results is available from the literature. Patt et al. [24] ana-
lyzed 5 GBMs and observed strong Kv10.1 expression in 3
out of 5 samples. Recently, Bai et al. [26] widely observed
Kv10.1 overexpression in both GBM cell lines and clinical
samples. To our knowledge, no investigation of Kv10.1 ex-
pression was previously performed in brain metastases.
Since brain cancers represent the most frequent forms in
adults and they are associated with a dismal overall
survival, the necessity to identify selective therapies to im-
prove the prognosis of the patients is mandatory.
In this study we have analyzed the expression of
Kv10.1 in GBMs and in brain metastases from different
carcinomas as well as the influence of Kv10.1 expression
in survival. Moreover, we have analyzed the overall sur-
vival in GBM and brain metastasis patients who had
undergone a post-operative therapy with tricyclic antide-
pressants, due to depression, and compared it with the
OS of those patients who did not, and correlated these
data with Kv10.1 expression.
Methods
Patients
Seventy-five consecutive patients with metastases to the
brain from different carcinomas have been included. In 30
of them we have comparatively analyzed the Kv10.1 ex-
pression in the corresponding primary carcinoma as well.
Furthermore, 71 patients with GBM were included for
analysis of Kv10.1 expression. All patients were treated
with tumor resection in the Department of Neurosurgery,
University of Goettingen, Germany from 2004–2011,
followed by adjuvant whole brain fractionated radiother-
apy for brain metastasis or by focal radiotherapy for GBM
(brain metastases: mean dose 35.8 Gray; GBM: mean dose
60 Gray) together with the alkylating drug temozolomide
in the GBM cohort, according to neuro-oncological stand-
ard regimes [13].
Because of depression, 23/75 brain metastases patients
and 26/71 GBM patients were additionally treated with
antidepressants encompassing the tricyclic amitriptyline,
the selective serotonin re-uptake inhibitors (SSRI) citalo-
pram and sertraline as well as the tetracyclic mirtazapine
(Table 1). Patients treated with additional long-term medi-
cation affecting the central nervous system (e.g. anticon-
vulsants) were not included in this study in order to avoid
bias. Protocols and dosage of antidepressants had been
chosen according to clinical standards. This study was
performed with the approval of the local ethics medical
committee, University of Goettingen (number 5/7/12).
Written informed consent was obtained from the patient
or patient caretaker.
Immunohistochemistry
For immunohistochemical analysis, formalin-fixed,
paraffin-embedded tumor tissues were used. Immunohis-
tochemical procedures were based upon formerly de-
scribed protocols [27]. Briefly, tumor tissue was cut into
5 μm sections and mounted on silane-covered slides. After
drying, sections were deparaffinized by rinsing in xylene
two times for 10 minutes each, followed by hydration
through an ethanol series (100-30 %, 5–2 min each). Anti-
gen retrieval was performed by heating the slides for
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30 min in 10 mM citrate buffer solution (pH: 6.0) at 90 °C
in a water bath. After the slides cooled down to room
temperature, non-specific binding sites were blocked
using 10 % BSA in TBS for 1 h. For antigen detection,
tissue sections were incubated with a recombinant single
chain anti-Kv10.1 antibody fused to alkaline phosphatase
(scFv62PhoA), in a dilution of 1:100 in TBS for 18 h at
24 °C. Subsequently, sections were washed 3x for 3 min
with detection buffer solution containing 100 mM Tris-
base, 100 mM NaCl and 5 mM MgCl2. Detection of alka-
line phosphatase activity was performed by incubating the
sections in BCIP/NBT (Roche Diagnostics, Rotkreuz,
Switzerland) for 20 min. Finally, the sections were coun-
terstained with Nuclear Fast Red (DAKO, Glostrup,
Denmark), dehydrated and mounted with coverslips.
In order to double-check the former results, a second
staining protocol was performed using the chromogen
Neufuchsin with some modifications: antigen retrieval
was performed by heating the slides for 30 min in a
steamer at 60-70 °C in Tris-EDTA buffer (pH: 9.0). Non-
specific binding sites were blocked with 0.2 % Casein for
20 min at room temperature. After the same antibody
incubation as above, alkaline phosphatase activity was
detected by incubating the sections in Neufuchsin solu-
tion (Sigma, Kawasaki, Japan), followed by counterstain-
ing with Haematoxylin.
For immunohistochemical evaluation we used a
Zeiss Axiovert 200 M inverted microscope (Carl Zeiss
Microscopy GmbH, Goettingen, Germany), provided
with a camera type Axiocam and Axiovision software.
Non-linear adjustments were not used.
The same antibody has previously been used to
characterize the distribution of Kv10.1 in human and
murine brain [1]. As a positive control, we used cerebral
tissue of adult C57/Bl6N mice to document the quality
of antibody preparations. As negative control, sections
were incubated with non-immune serum.
The stained tissue was analyzed semi-quantitatively
using a score previously described [27] with some modi-
fications as follows: Score 0, negative or less than 10 %
of the tumor cells showed staining; Score 1+, faint stain-
ing in more than 10 % of the tumor cells; Score 2+,
moderate staining in more than 10 % of the tumor cells;
Score 3+, strong staining in more than 10 % of the
tumor cells. Sections scored 0, 1+ were categorized as
Kv10.1 low, sections scored 2+, 3+ as Kv10.1 high. The
evaluation of the sections was performed by two experi-
enced observers blinded to the patient diagnosis.
Statistical analysis
The Kolmogorov-Smirnov-test was applied in order to
assess the normal distribution of data. Analyses of differ-
ences in survival time of patients partitioned in groups
according to Kv10.1 expression levels, antidepressant
treatment and clinical parameters were performed with
Student t-test or two-way ANOVA depending on the
number of variables. Furthermore, survival studies were
performed with the Kaplan-Meier analysis and the log-
rank test.
The impact of Kv10.1 expression on survival time was
evaluated using the Cox hazards regression analysis. For
the Cox regression analysis, proportional hazards were
considered. Proportionality was tested by the method of
Grambsch and Therneau. We estimated the univariate
effect on survival for each single Kv10.1 expression level
and then we have included in the models major clinical
predictors of outcome such as sex, gender, tumor
localization, KPS (Karnofsky performance status) extent
of surgical resection and RPA (recursive partitioning
analysis, the last one for metastasis patients) and TA
used, which allowed us control for the potential con-
founding effects, of these late variables. The final multi-
variate model included as covariates age, gender and
tumor localization. Likelihood ratio tests were used to
compare candidate models. A p-value <0.05 was consid-
ered statistically significant. Analyses were performed
using Prism version 6 (GraphPad Software Inc., La Jolla,
CA, USA) or SPSS Version 21 (SPSS Inc. der IBM
Company, Chicago, USA) for the Kaplan-Meier analysis.
Results
The male to female ratio was 1:0.9 in both GBMs and
metastases collectives. The median age at diagnosis of
patients with brain metastases was 60.7 years (SD: 12.7,
Table 1 Scoring of Kv10.1 expression in brain metastasis
patients regarding both localization of brain metastasis and type
of primary carcinoma
Localization n (%) Kv10.1 score
0 1+ 2+ 3+
Cerebellar 24 (32 %) 2 11 10 1
Frontal 23 (30.5 %) 5 8 7 3
Parietal 12 (16 %) 3 1 6 2
Temporal 10 (13.5) 1 3 6 0
Occipital 6 (8 %) 0 2 1 3
Primary carcinoma
Lung-carcinoma 37 (49 %) 7 11 13 6
Breast-carcinoma 14 (19 %) 2 8 4 0
Melanoma 6 (8 %) 1 1 3 1
Colorectal-carcinoma 4 (5 %) 0 1 3 0
Renal-cell-carcinoma 4 (5 %) 1 1 2 0
Ovarian-carcinoma 3 (5 %) 0 1 2 0
Prostate-carcinoma 2 (3 %) 0 1 1 0
Others 5 (7 %) 0 1 2 2
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range: 38–83 y.) and of patients with GBMs was
69.0 years (SD: 11.7, range: 30–84 y.).
Analysis of survival in brain metastases and GBMs
Results of the univariate analysis in metastasis patients
showed that better RPA class (I versus III and II versus
III) was associated with improved survival (χ2 = 32.721,
p = 0.01). In the group of GBMs, younger age of <45 y.
(χ2 = 8.535, p = 0.01), KPS > 70 (χ2 = 19.763, p = 0.03)
and extent of resection >98 % (χ2 = 21.765, p = 0.03)
were also associated with longer survival of patients, as
expected (log-rank test). In the multivariate Cox regres-
sion analysis of factors influencing survival in metasta-
ses, we have observed that low expression of Kv10.1 (p
= 0.04; RR = 1.448; 95 % CI = 1.041-1.914) and better
RPA class (p = 0.02; RR = 1.226; 95 % CI = 1.085-1.737)
remained their prognostic significance. In glioblastoma
patients, expression of Kv10.1 did not reach a prognos-
tic significance as KPS, age and extent of tumor resec-
tion entered Cox’s regression model.
Aberrant expression of Kv10.1 in brain metastases and
GBMs
A positive expression of Kv10.1 was observed in 64/75
(85.3 %) of brain metastases and in 55/71 (77.5 %) of
GBMs. Expression scores and tumor localization in the
brain as well as primary carcinoma of the brain metasta-
ses are shown in Table 1. Similarly, scores of Kv10.1 ex-
pression and tumor localization of the glioblastoma
samples are provided in Table 2. Figure 1 shows micro-
photographs of Kv10.1 expression in selected brain me-
tastasis and GBM, respectively.
Correlation of Kv10.1 expression and overall survival in
brain metastases and GBMs
Statistical analysis of the overall survival time showed that
patients bearing brain metastases with a low expression of
Kv10.1 had a significantly longer median survival time of
11 months (95 % CI: 7–13.7) compared to those patients
displaying a high expression of Kv10.1, who had a median
survival of only 6 months (95 % CI: 3 – 8.1, p = 0.012,
Fig. 2). In the GBM collective, patients with a low expres-
sion of Kv10.1 had a median survival of 13 months (95 %
CI: 9–17), whereas patients with a high expression of
Kv10.1 showed a median survival of 8 months (95 % CI:
5–15.6, p = 0.15, Fig. 2).
Correlation of Kv10.1 expression, treatment with
antidepressants and overall survival
Brain metastases patients, displaying a low Kv10.1 ex-
pression and who had additionally undergone a treat-
ment with antidepressants showed a significantly longer
overall survival (median OS: 13 months, 95 % CI: 6.1-
22.8) compared to untreated patients also displaying a
low Kv10.1 expression (median OS: 10 months, 95 % CI:
7–14.7, p = 0.03, log-rank test, Fig. 3). This positive
correlation could not be observed in brain metastasis pa-
tients with a high Kv10.1 expression also undergoing an-
tidepressants treatment (median OS of treated patients:
6 months, 95 % CI: 3–9.9; median OS of untreated pa-
tients: 6 months, 95 % CI: 3–9, p = 0.1, log-rank test).
Table 3 shows the univariate analysis of Kv10.1 expres-
sion, gender, tumor localization and survival in patients
with brain metastases. Kaplan-Meier analysis of survival
of brain metastasis patients showing differences in OS
depending on expression of Kv10.1 and treatment with
antidepressants is shown in Fig. 4. Furthermore, by
multivariate Cox hazard analysis, a significant associ-
ation was observed between low expression of Kv10.1
and longer survival time (p = 0.04, 95 % CI: 0.361-0.989).
In contrast, the expression of Kv10.1 in GBM patients
showed no significant influence on survival, independ-
ently of antidepressants therapy (p > 0.5, log rank test
and Kaplan-Meier analysis, not shown) [24, 28].
Comparative analysis of Kv10.1 expression in brain
metastases and corresponding primary carcinomas
The expression of Kv10.1 was higher in brain metastases
compared to the primary carcinomas in 60 % of the 30 an-
alyzed matched pairs. It remained unchanged in 26.7 %
and it was lower in 13.3 %. Analysis of groups of Kv10.1
expression showed significant differences regarding score
0 and 1 (see Methods for scoring; more frequent in pri-
mary tumors, p = 0.04 and 0.035, respectively) and score 2
(more frequent in brain metastases, p = 0.038). Survival of
patients showing a low expression of Kv10.1 in both
primary tumor and corresponding brain metastasis was
significantly longer (p = 0.035).
Discussion
Brain metastasis and GBM are the most frequent brain
tumors in adults. In general, 6 % of patients with a newly
diagnosed primary carcinoma will develop brain metas-
tasis during cancer lifetime, based on USA data sets
through Centers for Disease Control and Prevention and
Surveillance, Epidemiology and End Results (SEER) Pro-
gram [29]. This incidence is rapidly growing because of
increasingly available diagnostic procedures allowing
more accurate and earlier detection and because more
efficient therapy modalities with better control of pri-
mary carcinoma and longer survival. The incidence of
GBM based on data from the Central Brain Tumor
Registry of the United States (CBTRUS, www.cbtrus.org)
reaches 16 % of all primary CNS tumors and it is the
most frequent astrocytic tumor (54 %) in adults. Both
brain cancers are currently incurable. The median sur-
vival time of patients with brain metastasis based on the
Recursive Partitioning analysis, RPA of the Radiation
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Therapy Oncology Group, RTOG [30] and on the
Graded Prognostic Assessment, GPA [31] is 11 months
after surgery and cranial radiotherapy. Furthermore,
chemotherapy in brain metastasis plays only a secondary
role, since large molecules developed for the treatment
of primary carcinomas are not suitable to go through
the blood brain barrier, making these malignancies in-
accessible for currents drugs.
In the case of GBM, the scenario is also dismal with a
median survival rate of 15 months in spite of multi-
modal treatment including gross-total resection, radio-
therapy and chemotherapy, with the alkylating drug
temozolomide, whereas the 2-year survival rate is below
14 % (CBTRUS). This survival rate is somehow higher in
patients after gross-total resection of tumor, post-
operative radiotherapy and concomitant chemotherapy
with temozolomide, with GBM carrying promoter hyper-
methylation of the DNA repair gene MGMT, which oc-
curs in 35-40 % of the cases [32, 33]. Taking this into
consideration, every effort to delineate new therapeutic
approaches is urgently needed.
Under physiological conditions, Kv10.1 expression is
restricted to the central nervous system, and it is not
normally expressed in differentiated peripheral tissues
[1]. On the contrary, Kv10.1 is overexpressed in a variety
of cell lines derived from human malignancies and in
different cancers including head and neck, gastric, colon,
hepatocellular pancreatic, renal or prostate carcinoma
[4–6, 12, 14, 27] within which Kv10.1 enhances the pro-
liferation of the cells and is required for the maintenance
of growth. In these cases, Kv10.1 is not detected in the
surrounding tissues.
One of the most striking characteristics of Kv10.1 is
its relationship to cellular transformation. Kv10.1 chan-
nels are necessary for progression through the G1
phase and G0/G1 transition of the cell cycle [3]. Cells
transfected with Kv10.1 lose contact inhibition, and in-
duce aggressive tumors when implanted into immune-
depressed mice [4]. Moreover, specific inhibition of
Kv10.1 expression by the antisense technique, siRNA
[20], or antibodies [19], leads to a reduction in tumor
cell proliferation in vitro and in vivo. How overexpres-
sion of Kv10.1 occurs might be explained through
deregulation of the pathway p53/miRNA34/E2F1. p53
negatively regulates Kv10.1 expression, thus inactivation
of p53, as is the case in many cancers including second-
ary GBM, can cause oncogenic overexpression of
Kv10.1 [34]. These findings support the molecular
Fig. 1 Examples of immunohistochemical analyses of Kv10.1 in brain metastasis and glioblastoma multiforme. a. NBT/BCIP staining of Kv10.1 (left)
counterstaining nuclear fast red as positive control of Kv10.1 expression (adult C57BI6N mouse, cortical tissue) and b. Neufuchsin staining of
Kv10.1 (right) counterstaining Haematoxylin (both magnification 400x, scale bar 50 μm). c NBT/BCIP staining of Kv10.1 (grade 2) in a brain
metastasis of lung carcinoma (magnification 40x, scale bar 50 μm). d Neufuchsin staining of Kv10.1 (grade 2) in a brain metastasis of lung
carcinoma, counterstaining Haematoxylin (both magnification 40x, scale bar 50 μm). e. NBT/BCIP staining of Kv10.1 in GBM (grade 3),
counterstaining nuclear fast red, (magnification 40x, scale bar 50 μm). f. Neufuchsin staining of Kv10.1 (grade 3) in GBM, counterstaining
Haematoxylin (magnification 40x, scale bar 50 μm)
Table 2 Kv10.1 expression scoring regarding brain localization
of glioblastoma multiforme
Localization n (%) Kv10.1 score
0 1+ 2+ 3+
Temporal 26 (36.6 %) 5 7 13 1
Frontal 25 (35.2 %) 4 13 7 1
Parietal 18 (25.4 %) 6 7 5 0
Occipital 2 (2.8 %) 1 0 1 0
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mechanisms associated with overexpression of Kv10.1
in tumor pathogenesis and add Kv10.1 to the p53/
miRNA34/E2F1 regulator pathway with Kv10.1 mediat-
ing cell growth.
We have previously provided the link between the
Kv10.1 channel and the mechanism to block this channel
through drugs such as charged forms of antidepressants
and astemizole which bind Kv10.1 to sites in the intracel-
lular portion of the permeation pathway, only accessible
when the channels are open (31). Tricyclic antidepressants
(TA) such as imipramine, chlorimipramine, citalopram
and amitriptyline have been previously reported to have
anticancer properties [35–37]. Furthermore, cytotoxic ef-
fects have been demonstrated in various cancer cell lines
including glioma cells [35–37] and colorectal cancer cells
(35). Animal studies substantiate an anticancer action in
various cancer experimental models, such as sarcoma and
lymphocytic leukaemia [38, 39]. Jahchan [40] observed
that TA induce apoptosis in small cell lung cancer (SCLC)
cells in culture, and in mouse and human SCLC tumors
transplanted into immuno-compromised mice. In these
models, treatment with TA led to apoptotic cell death by
activation of caspase-3, possibly through disruption of
autocrine survival signals, even at doses used normally to
treat depression. Moreover, the same apoptotic effect
could be seen in high-grade neuroendocrine tumors, such
as Merkel cell carcinoma, pheochromocytoma, and
neuroblastoma.
Regarding gliomas and TA, a recent study suggested
that the antidepressant desipramine could induce au-
tophagy in C6 glioma cells through the PERK-ER
(RNA–like endoplasmic reticulum kinase) stress path-
way [41]. Imipramine has already been demonstrated to
reduce cell proliferation, inhibit the PI3K/Akt/mTOR
signaling pathway and to induce autophagic cell death in
human glioma cells [42]. Furthermore, Levkovitz showed
that selected antidepressants induce apoptosis in neur-
onal and glial cell lines by activation of p-c-Jun and sub-
sequent increased mitochondrial released Cyt c [37].
To date, no data is available regarding expression of
Kv10.1 in brain metastases. Furthermore, no molecular
or clinical data is available concerning treatment with
TA and survival in patients with brain metastases. In the
present series we have expanded the significance of
Kv10.1 in cancer to brain metastasis and GBM. Interest-
ingly, in the case of brain metastasis, this phenomenon
was independent of the histology of the primary carcin-
oma, suggesting that this event is related to the progres-
sion of disease, probably providing tumor cells a survival
advantage under conditions frequently occurring in can-
cer, most probably hypoxia. A close consequence of hyp-
oxia in cancer is an up-regulation of HIF-1, which is
Fig. 2 Association between survival and Kv10.1 expression in
glioblastoma multiforme and brain metastasis patients. Analysis of
overall survival in GBM and brain metastases patients depending on
Kv10.1 expression revealing a significantly longer overall survival in
those patients with brain metastases showing low expression of
Kv10.1, as compared with brain metastases carrying a high
Kv10.1 expression
Fig. 3 Relationship between Kv10.1 low-expression, therapy with
antidepressants and overall survival in metastasis patients. Box-Whisker
plot of median overall survival in brain metastases patients depending
on Kv10.1 expression and antidepressants treatment therapy. A
significantly longer median survival time in those patients with
metastases with both low Kv10.1 expression and TA treatment is
observed in the Kaplan-Meier analysis
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hallmark of cancer [43]. We had previously observed an
increase in HIF-1 activity in Kv10.1-expressing cells,
which represents a novel explanation for the oncogenic
potential of Kv10.1 [17]. This hypothesis is further sup-
ported by the fact that the expression of Kv10.1 in brain
metastases, compared to the expression in the corre-
sponding primary carcinomas, was significantly higher in
60 % of the cases.
TA are currently used in clinical routine to treat a var-
iety of diseases, such as major depression, neuropathic
pain and fibromyalgia. TA were also shown to inhibit acid
sphyngomyelinase (ASM), an enzyme catalyzing the hy-
drolysis of sphingomyelin to ceramide. Both, ASM and
ceramide play an important role in different pathologies
including diabetes, cystic fibrosis, major depression,
Alzheimer’s disease and also in cancer. Blocking the syn-
thesis of ceramide by inhibiting ASM introduced new
therapy options for the treatment of the above mentioned
diseases. In 2013, Peterson et al. reported that inhibition
of acid sphingomyelinase selectively destabilizes cancer
cell lysosomes, triggers cancer-specific lysosomal cell
death, and reduces tumor growth in vivo [44]. Thus, can-
cer cells might fail to maintain sphingomyelin hydrolysis
during exposure to ASM-inhibitors, such as tricyclic anti-
depressants, resulting in lysosomal destabilization due to
sphingomyelin accumulation.
Sinergistic strategies of acid sphingomyelinase inhib-
ition together with conventional chemotherapeutics and/
or irradiation have been tested with promising results,
also on glioma cells [45]. Nevertheless, a recent analysis
showed that death of glioma cells after standard radio-
and chemotherapy was not influenced by modulation of
acid sphyngomyelinase and/ or glucosylceramide syn-
thase pathway [46]. The last authors also observed a lack
of association between modulation of the ceramide path-
way and survival time of a large cohort of 564 studied
patients with gliomas grade II, III and IV. This recent
study has put into perspective the actual, probably less
important significance, of the ceramide pathway in gli-
omas. Concerning brain metastases, no studies are avail-
able from the literature analyzing the influence of acid
sphyngomyelinase on tumor progression or patient
survival.
The translational impact of our results is highlighted
by the observation that a significantly longer patient sur-
vival is associated with a lower Kv10.1 expression in the
group with brain metastases, which confirms similar ob-
servations in non-CNS tumors, such as acute myeloid
leukemia [8]. Contrastingly, we could not observe such a
significant association in GBM. This observation would
Fig. 4 Analysis of survival in brain metastasis patients considering
Kv10.1 expression and antidepressants therapy. Kaplan-Meier analysis
of overall survival of patients with brain metastases depending on
Kv10.1 expression and on antidepressant treatment. A significantly
longer survival time in those brain metastasis patients with a
low expression of Kv10.1 who had undergone treatment with
antidepressants is observed
Table 3 Univariate analysis of correlations between Kv10.1
expression, antidepressant therapy, gender and tumor
localization in patients with brain metastases
Parameter Number of cases Survival (months) p-value
n (%) median (95 % CI)
Eag1 expression
High 39 (52 %) 6 (3 – 8.1)




Treated 8 (10.7 %) 6 (3 – 9.9)
Untreated 27 (36 %) 6 (3 – 9) 0.1
Eag1 low
Treated 10 (13.3 %) 13 (6.1 – 22.8)
Untreated 25 (33.3 %) 10 (7 – 14.7) 0.03
Gender
Male
Eag1 high 26 (34.7 %) 6.2 (3.9 – 8.5)
Eag1 low 13 (17.3) 10.6 (6.4 – 14.8) 0.039
Female
Eag1 high 13 (17.3 %) 10.15 (6.1– 14.2)
Eag1 low 23 (30.7 %) 11.65 (9 – 14.3) 0.5
Tumor localization of brain metastases
Fronto-parietal
Eag1 high 18 (24 %) 6.5 (3 – 10)
Eag1 low 17 (22.7 %) 10 (7 – 16.9) 0.15
Temporo-occipital
Eag1 high 10 (13.3 %) 6.5 (3 – 14.1)
Eag1 low 6 (8 %) 8.5 (5.2 – 16.2) 0.6
Cerebellar
Eag1 high 11 (14.7 %) 5 (2.8 – 8.2)
Eag1 low 13 (17.3 %) 13 (5.6 – 16.4) 0.03
Significant p-values are italicized
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indicate a secondary role of Kv10.1 in GBM progression
[24], although it does not preclude the potential rele-
vance of the channel in other aspects of GBM, such as
resistance to interferon [28]. One of the mechanisms via
which overexpression of Kv10.1 contributes to tumor
progression is an up-regulation of HIF1- and VEGF- me-
diated angiogenesis pathways. Taking into consideration
that neo-angiogenesis is known to be up-regulated in
GBM, one may argue that such up-regulation of angio-
genesis associated factors is also achieved through
Kv10.1 independent transduction signals.
Brain metastases patients showing a low Kv10.1 ex-
pression and treated with TA showed in our investiga-
tion a significantly longer overall survival compared to
patients without TA therapy. In contrast, treatment with
the antidepressant mirtazapine, a HERG (human Ether-
à-go-go-Related Gene) channel blocker did not show
this effect. These results strongly suggest that blocking
Kv10.1 with TA in patients with low Kv10.1 expression
might be relevant for tailored therapy of brain metasta-
ses. The fact that Kv10.1 blockade with TA are not
significantly effective in patients with high Kv10.1 ex-
pression could indicate that the partial inhibition of
Kv10.1 is not enough to alter the behavior of those
highly malignant cases. Alternatively, it may be under-
stood by taking into consideration previous results of
our group [17]. Although no mutations in Kv10.1 have
been reported in cancer, high expression of Kv10.1 may
be linked with point mutations leading to conform-
ational changes that could affect sensitivity to TA while
maintaining intact its oncogenic potential, which is only
partly dependent on ion permeation [17]. Nevertheless,
this hypothesis needs further investigation.
Conclusions
In summary, we have demonstrated for the first time that
Eag1 is overexpressed in brain metastases of different pri-
mary carcinomas and that high Kv10.1 expression is asso-
ciated with significantly poorer survival of patients.
Moreover, inhibition of Kv10.1 with TA was associated
with a significant longer survival time in brain metastasis
patients and strongly suggests that Kv10.1 has a role in cell
proliferation in these brain tumors as observed in non-
CNS malignancies. These results underscore Kv10.1 as a
potential tool in the tailored management of brain metas-
tases and probably of glioblastoma multiforme as well.
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